Intervention Protocol

Heliox for prevention of morbidity and mortality in ventilated newborn infants

  1. Eleanor J Molloy1,*,
  2. Naomi McCallion1,
  3. Colm PF O'Donnell1,
  4. Peter G Davis2

Editorial Group: Cochrane Neonatal Group

Published Online: 16 JUL 2008

Assessed as up-to-date: 7 MAY 2008

DOI: 10.1002/14651858.CD007304


How to Cite

Molloy EJ, McCallion N, O'Donnell CPF, Davis PG. Heliox for prevention of morbidity and mortality in ventilated newborn infants (Protocol). Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD007304. DOI: 10.1002/14651858.CD007304.

Author Information

  1. 1

    National Maternity Hospital, Neonatal Unit, Dublin 2, Ireland

  2. 2

    Royal Women's Hospital, Department of Obstetrics and Gynaecology, Carlton, Victoria, Australia

*Eleanor J Molloy, Neonatal Unit, National Maternity Hospital, Holles Street, Dublin 2, Ireland. emolloy@nmh.ie. elesean@hotmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 16 JUL 2008

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the effect of Heliox on rates of mortality, neurodevelopmental impairment and bronchopulmonary dysplasia in ventilated infants and to evaluate the safety profile of heliox in this population.

Subgroups:

  1. Preterm infants
  2. Infants wtih evolving or established chronic lung disease